Question 1

How does dose affect elimination half-life in nonlinear pharmacokinetics?

Accepted Answer

In nonlinear pharmacokinetics, elimination half-life extends as dose increases, unlike linear kinetics where it remains constant. This occurs because the Michaelis-Menten parameters—Michaelis constant (KM) and maximum process rate (Vmax)—along with plasma concentration influence elimination. As dosage rises, clearance reduces and the area under the curve becomes disproportionately larger, creating a dose-dependent relationship.

Question 2

Why does drug clearance decrease with increasing doses in nonlinear kinetics?

Accepted Answer

Drug clearance decreases with increasing doses due to saturation of metabolic enzymes or renal transport systems. When enzyme capacity becomes saturated, the rate of drug elimination cannot increase proportionally with dose. This saturation phenomenon causes clearance to decline, resulting in higher-than-expected plasma concentrations and extended elimination half-lives at elevated doses.

Question 3

What is enzymatic saturation and how does it affect drug metabolism?

Accepted Answer

Enzymatic saturation occurs when metabolic enzymes reach their maximum capacity and cannot process additional drug molecules at a faster rate. This is particularly observed in special populations like infants or slow metabolizers. When saturation happens, metabolism shifts from first-order to zero-order kinetics, causing dose-dependent changes in drug clearance and plasma concentrations that deviate from expected linear relationships.

Question 4

How does paroxetine demonstrate nonlinear pharmacokinetics through CYP2D6 inhibition?

Accepted Answer

Paroxetine exhibits nonlinear pharmacokinetics because it undergoes extensive metabolism via CYP2D6 and causes autoinhibition at clinical doses. As paroxetine concentrations increase, it inhibits its own metabolism enzyme, leading to disproportionately higher plasma levels than expected from dose increases. This saturation of CYP2D6 results in an elimination half-life of approximately 21 hours and potential drug-drug interactions with other CYP2D6-metabolized medications.

Question 5

What clinical consequences occur when slow metabolizers receive standard drug doses?

Accepted Answer

Slow metabolizers experience significantly higher plasma levels and substantially greater area under the curve than normal metabolizers receiving equivalent doses. For example, the beta-adrenergic antagonist metoprolol shows extensive metabolism in normal individuals but exhibits nonlinear kinetics in slow metabolizers. This altered pharmacokinetics increases the risk of adverse effects and requires dose adjustments to maintain therapeutic safety in these patient populations.

Question 6

How can clinicians identify when a drug follows nonlinear kinetics?

Accepted Answer

Clinicians can identify nonlinear kinetics when elimination half-life increases with plasma concentration while metabolic or renal function remains stable. Additionally, if the area under the curve increases disproportionately with dose increases, this signals nonlinear behavior. Deriving clearance from the Michaelis-Menten equation for drugs following a one-compartment model can confirm nonlinear kinetics and help predict dose-dependent pharmacokinetic changes.

Question 7

What drug-drug interactions can occur with paroxetine due to CYP2D6 inhibition?

Accepted Answer

Paroxetine inhibits CYP2D6 metabolism of other drugs, including desipramine, risperidone, and atomoxetine, potentially causing elevated plasma concentrations of these medications. Additionally, paroxetine can inhibit metabolism of selective serotonin reuptake inhibitors and monoamine oxidase inhibitors, risking serotonin syndrome. Understanding these interactions is crucial for optimizing dosing strategies and minimizing adverse effects in patients receiving multiple medications.

פארמקוקינטיקה לא ליניארית: תלות בחצי החיים של סילוק ובבהירות מינון

Browse More Videos